Hims & Hers Health Inc : TD Cowen Cuts Target Price to $30 From $37

THOMSON REUTERS01-23

Hims & Hers Health Inc : TD Cowen Cuts Target Price to $30 From $37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Cedric77
    01-27
    Cedric77
    Sharing my Read from Gd Financial  Cents and why the price dipped. In mid 2025, Hims traded like a runaway winner. Market cap around $12.8B. Six months later, it sat around $6.94B. That is about $6.5B erased. And the reason has almost nothing to do with hair loss or ED. Hims built a clean business for years: Simple diagnoses. Fast shipping. Subscription revenue across hair, sexual health, dermatology, and mental health. Then they caught the biggest consumer health wave of the decade. Weight loss injections. Not the brand name versions. The cheaper compounded versions that exploded during shortages. That product line turned Hims into a rocket ship. It helped drive a massive jump in revenue and delivered the company’s first annual profit, according to the Financial Times. But the decisi
Leave a comment
1
1